Clinical trials of combining nivolumab and ipilimumab or nivolumab monotherapy in patients with stage IV melanoma are still ongoing.572 Besides, combined targeted therapies like BRAF inhibitor dabrafenib plus MEK inhibitor trametinib have demonstrated improved RFS and tolerable toxicity in patients with stage III BRAFV600R/K-mutant melanoma compared with the adjuvant use of placebo.573 Both anti-PD-1 treatment and BRAFi plus MEKi therapy are the frontline options for adjuvant therapy. Here, MAP2K7 is linked to melanoma.